Acute Porphyria Drug Database

J07BK02 - Zoster, Live Attenuated
Propably not porphyrinogenic
PNP

Rationale
Based on its pharmacokinetics properties the zoster vaccine has no conceivable porphyrinogenic effects.
Chemical description
Varicella-zoster virus live, attenuated. Produced in human diploid cells
Therapeutic characteristics
The zoster-vaccine is indicated for prevention of herpes zoster and herpes zoster-related post-herpetic neuralgia (PHN), in individuals over 50 years. The vaccine can be injected subcutaneously or intramuscularly as a single dose.
Metabolism and pharmacokinetics
The zoster vaccine is not metabolized by the cytochrome P450 system.

References

  1. Government bodies
  2. Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015). #1857
  3. Summary of Product Characteristics
  4. The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Zostavax. (Last edition: February. 2016). #1884

Similar drugs
Explore alternative drugs in similar therapeutic classes J07B / J07BK or go back.

 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙